Drugs / ISIS CRP Rx
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01710852 | Oct 2012 → Apr 2014 | paroxysmal atrial fibrillation | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01414101 | Aug 2011 → May 2013 | rheumatoid arthritis | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2013-08-05 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients With Rheumatoid Arthritis ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that patients treated with ISIS-CRPRx achieved rapid, dose-dependent mean reductions of up to 67 percent in C-reactive protein (CRP) in a Phase 2 study in patients with rheumatoid arthritis (RA). |
| 2013-03-13 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx ionis.com ↗ |
| 2011-02-23 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study ionis.com ↗
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein (CRP) in the cohort of subjects in the study with elevated CRP. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-08-05 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients With Rheumatoid Arthritis ionis.com ↗ |
| 2013-03-13 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx ionis.com ↗ |
| 2011-02-23 | Ionis Pharmaceuticals | Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study ionis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS-CRPRx | “evaluated the pharmacodynamics, safety and tolerability of ISIS 329993 (ISIS-CRPRx), an antisense oligonucleotide, in patients with active rheumatoid arthritis (RA).” PMID 25885521 ↗ Mar 2015 |
| Known as | ISIS 329993 | “evaluated the pharmacodynamics, safety and tolerability of ISIS 329993 (ISIS-CRPRx), an antisense oligonucleotide, in patients with active rheumatoid arthritis (RA).” PMID 25885521 ↗ Mar 2015 |
| Action | Inhibit | “ISIS-CRPRx selectively reduced hs-CRP” PMID 25885521 ↗ Mar 2015 |
| Modality | Antisense oligonucleotide | “a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein” PMID 25885521 ↗ Mar 2015 |
| Route | Subcutaneous | “via subcutaneous (SC) injection” PMID 25885521 ↗ Mar 2015 |
| Target | CRP | “ISIS 329993 Targeting CRP” NCT01710852 ↗ |